Kate Haviland

Kate Haviland is an accomplished executive in the biotechnology sector with extensive leadership experience. Currently serving as the Chief Executive Officer at Blueprint Medicines, Kate has also held the positions of Chief Operating Officer and Chief Business Officer at the same company. Additionally, Kate serves as the Chairman of the Board of Directors at Fulcrum Therapeutics and has held senior roles at Idera Pharmaceuticals, Sarepta Therapeutics, and PTC Therapeutics, contributing significantly to rare diseases and oncology program management. Kate holds a BA in Biochemistry/Molecular Biology and Economics from Wesleyan University and an MBA from Harvard Business School.